Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Model shows booster doses and antiviral pills may enable relaxation of SARS-CoV-2 social distancing

Model shows booster doses and antiviral pills may enable relaxation of SARS-CoV-2 social distancing

SARS-CoV-2 nucleocapsid G215C variation may explain Delta severity

SARS-CoV-2 nucleocapsid G215C variation may explain Delta severity

Study investigates population immunity to SARS-CoV-2 through heterogenous pathways

Study investigates population immunity to SARS-CoV-2 through heterogenous pathways

New COVID-19 test can determine if individuals have been vaccinated, infected, both, or neither

New COVID-19 test can determine if individuals have been vaccinated, infected, both, or neither

Study suggests SARS-CoV-2 Omicron showed increased household transmission and immune evasion in Norway

Study suggests SARS-CoV-2 Omicron showed increased household transmission and immune evasion in Norway

Spillover of SARS-CoV-2 Omicron variant infection in white-tailed deer in New York

Spillover of SARS-CoV-2 Omicron variant infection in white-tailed deer in New York

Excess COVID-19 mortality in Eastern Europe linked to lower vaccination rates and weak implementation of regulations

Excess COVID-19 mortality in Eastern Europe linked to lower vaccination rates and weak implementation of regulations

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Clinical severity of COVID-19 caused by SARS-CoV-2 variants and the effectiveness of mRNA vaccines against them

Clinical severity of COVID-19 caused by SARS-CoV-2 variants and the effectiveness of mRNA vaccines against them

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Study explores protection against Omicron and Delta infections by COVID-19 vaccination and previous infection

Study explores protection against Omicron and Delta infections by COVID-19 vaccination and previous infection

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

The effect of Omicron mutations at the fundamental atomic scale level

The effect of Omicron mutations at the fundamental atomic scale level

Comparison of SARS-CoV-2 test performance by sample type and modality in close contacts of SARS-CoV-2 cases

Comparison of SARS-CoV-2 test performance by sample type and modality in close contacts of SARS-CoV-2 cases

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.